The science behind the most-prescribed peptide stack in the US: mechanisms of action, Phase 2 clinical data, GHRH+GHRP synergy, and evidence quality by application area.
Research Disclaimer: This page summarizes published research for educational purposes. CJC-1295 and ipamorelin are not FDA-approved for general human use. All data cited is from peer-reviewed publications or registered clinical trials.
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), the hypothalamic peptide that signals the pituitary gland to produce and release growth hormone. It is a modified version of the first 29 amino acids of native GHRH (Mod GRF 1-29), with four amino acid substitutions that dramatically improve plasma stability by protecting against enzymatic degradation. The "with DAC" variant adds a Drug Affinity Complex that binds albumin in the bloodstream, extending the half-life from approximately 30 minutes to 6–8 days.
Ipamorelin is a synthetic pentapeptide that acts as a selective agonist at the ghrelin receptor (GHS-R1a), making it a growth hormone-releasing peptide (GHRP). Unlike the hypothalamic GHRH pathway that CJC-1295 activates, ipamorelin works through a completely separate intracellular signaling cascade involving protein kinase C and intracellular calcium mobilization. This mechanistic independence is precisely what makes the combination synergistic rather than merely additive.
The combination is the most commonly prescribed peptide stack in US anti-aging and hormone optimization clinics, largely because it produces greater GH output than either compound alone while ipamorelin's selectivity profile avoids the cortisol and prolactin elevation associated with older GHRPs like GHRP-2 and GHRP-6. The Raun et al. 1998 study established ipamorelin as the first GHRP to achieve potent GH release without significant cortisol stimulation — a distinction that remains clinically relevant today.
The synergy between GHRH analogs and GHRPs was first characterized by Bowers et al. in 1990 and has been replicated across multiple subsequent studies. When a GHRH analog binds its receptor on pituitary somatotroph cells, it activates adenylyl cyclase, increasing intracellular cyclic AMP (cAMP). This triggers protein kinase A (PKA), which phosphorylates voltage-gated calcium channels and ultimately drives GH secretory vesicle exocytosis.
When ipamorelin simultaneously binds the ghrelin receptor (GHS-R1a) on the same somatotroph cell, it activates phospholipase C via a G-protein-coupled mechanism, generating inositol trisphosphate (IP3) and diacylglycerol (DAG). This activates protein kinase C (PKC) and mobilizes intracellular calcium from the endoplasmic reticulum — a completely separate calcium signal from the one triggered by GHRH.
The result of activating both the cAMP/PKA and IP3/PKC pathways simultaneously is a multiplicative increase in intracellular calcium that drives GH exocytosis far beyond what either pathway alone can achieve. Studies have documented GH release 2–10 times greater with the combination than with either compound alone — a true pharmacological synergy that explains the stack's clinical dominance.
Teichman SL et al. J Clin Endocrinol Metab. 2006;91(3):799-805
65 healthy adults randomized to CJC-1295 DAC (30–120 mcg/kg) or placebo. Single injection produced dose-dependent GH increases of 2–10 fold and IGF-1 increases of 1.5–3 fold sustained for 6 days. Repeated weekly dosing maintained IGF-1 elevation for 28 days. Well-tolerated; most common side effects were flushing and injection site reactions.
CJC-1295 binds albumin via the DAC moiety, extending half-life from ~7 minutes (native GHRH) to 6–8 days. Sustained GHRH receptor activation drives continuous GH synthesis and pulsatile release.
Very High — the foundational clinical pharmacology paper for CJC-1295; all dosing rationale derives from this study
Raun K et al. Eur J Endocrinol. 1998;139(5):552-561
Ipamorelin produced potent, dose-dependent GH release in rats comparable to GHRP-6, but unlike GHRP-6 and GHRP-2, did not stimulate cortisol, ACTH, or prolactin at any dose tested. This selectivity profile was unique among GHRPs studied at the time.
Ipamorelin acts as a selective ghrelin receptor (GHS-R1a) agonist. Its selectivity appears to result from its inability to activate the ACTH/cortisol pathway that older GHRPs trigger through off-target receptor interactions.
Very High — established ipamorelin's safety advantage over GHRP-2 and GHRP-6; the reason it became the preferred GHRP for stacking
Bowers CY et al. J Clin Endocrinol Metab. 1990;70(4):975-982
Combined administration of GHRH and a GHRP produced GH release significantly greater than the sum of each compound alone — demonstrating true pharmacological synergy. The combination activated both the cAMP (GHRH) and PKC (GHRP) intracellular pathways simultaneously.
GHRH receptor activation increases intracellular cAMP; GHS-R1a activation increases intracellular calcium via PKC. Simultaneous activation of both pathways creates a multiplicative effect on GH secretory vesicle exocytosis.
High — the mechanistic basis for why CJC-1295 + ipamorelin produces greater GH output than either alone
Alba M et al. J Clin Endocrinol Metab. 2006;91(7):2482-2488
Modified GRF 1-29 showed significantly improved plasma stability vs native GHRH 1-29, with a half-life of approximately 30 minutes vs ~7 minutes for unmodified GHRH. Produced robust GH pulses with subcutaneous administration.
Four amino acid substitutions (positions 2, 8, 15, 27) protect against enzymatic cleavage by dipeptidyl peptidase IV and other plasma proteases, extending the functional half-life without albumin binding.
High — pharmacokinetic basis for the without-DAC formulation preferred in pulsatile dosing protocols
Greenwood-Van Meerveld B et al. J Pharmacol Exp Ther. 2012;340(3):637-644
Ipamorelin accelerated gastrointestinal motility recovery after abdominal surgery in a Phase 2 human trial. Patients receiving ipamorelin had significantly shorter time to first bowel movement and reduced hospital stay vs placebo.
Ghrelin receptor (GHS-R1a) activation in the enteric nervous system promotes gastrointestinal motility independently of GH release — demonstrating ipamorelin's peripheral actions beyond GH stimulation.
Moderate — important as human clinical evidence for ipamorelin; the GI motility mechanism is separate from the GH-releasing mechanism
Sigalos JT, Pastuszak AW. Sex Med Rev. 2018;6(1):45-53
Review of GHRH analog and GHRP safety data in adults. Found no evidence of pituitary desensitization or downregulation with chronic use. Unlike exogenous HGH, GHRH analogs preserve the pituitary's natural feedback mechanisms via somatostatin. No cases of acromegaly or IGF-1 excess reported in clinical literature.
GHRH analogs stimulate endogenous GH production, which is subject to normal negative feedback via IGF-1 and somatostatin. This self-limiting mechanism prevents the supraphysiological IGF-1 levels associated with exogenous HGH.
High — key safety comparison vs HGH; supports the long-term safety profile of GHRH-based protocols
Walker RF. Rejuvenation Res. 2006;9(1):3-5
Review of GHRH analog therapy in adults with age-related GH decline showed significant improvements in IGF-1 normalization, lean body mass, and fat mass reduction with combined GHRH + GHRP protocols. Effects were comparable to low-dose HGH replacement at a fraction of the cost.
Combined GHRH + GHRP therapy restores youthful GH pulsatility patterns. Increased GH and IGF-1 promote lipolysis, protein synthesis, and lean mass accretion through established anabolic signaling pathways.
High — supports the body composition rationale for the CJC-1295 + ipamorelin stack in age-related GH decline
| Compound | Type | Half-Life | Dosing | Cortisol Effect | Selectivity |
|---|---|---|---|---|---|
| CJC-1295 with DAC | GHRH Analog | 6–8 days | 1–2x/week | No effect | GH/IGF-1 |
| CJC-1295 without DAC (Mod GRF 1-29) | GHRH Analog | ~30 min | Daily (pre-sleep) | No effect | GH/IGF-1 |
| Ipamorelin | GHRP / Ghrelin Mimetic | ~2 hours | 2–3x/day | No effect ★ | GH only |
| GHRP-6 | GHRP | ~2 hours | 2–3x/day | Elevated (+30%) | GH + cortisol |
| GHRP-2 | GHRP | ~1 hour | 2–3x/day | Elevated (+50%) | GH + cortisol + prolactin |
| Sermorelin | GHRH (full sequence) | ~10 min | Daily (pre-sleep) | No effect | GH/IGF-1 |
The choice between CJC-1295 with DAC and without DAC (Mod GRF 1-29) is the primary protocol decision. The with-DAC version produces sustained GH/IGF-1 elevation from weekly injections; the without-DAC version produces pulsatile GH spikes that more closely mimic natural physiology. Most researchers prefer the without-DAC version when prioritizing physiological GH pulsatility.
Rationale: Mimics natural GH pulsatility; maximizes overnight GH pulse during slow-wave sleep
Rationale: Sustained IGF-1 elevation from CJC-DAC; ipamorelin adds pulsatile spikes on top
Rationale: Conservative cycling preserves pituitary sensitivity; common in longevity-focused protocols
| Application | Evidence Level | Human Data | Notes |
|---|---|---|---|
| GH Stimulation | Strong | Phase 2 RCT (Teichman 2006) | 2–10x GH increase; most replicated finding |
| IGF-1 Elevation | Strong | Phase 2 RCT | 1.5–3x sustained increase with CJC-DAC |
| Body Composition (lean mass) | Moderate | Review data | Indirect via GH/IGF-1; no dedicated RCT |
| Fat Loss | Moderate | Review data | GH-mediated lipolysis; no dedicated RCT |
| Sleep Quality | Limited | Anecdotal | GH secretion peaks in slow-wave sleep; no direct trial |
| Recovery / Tissue Repair | Limited | None | Plausible via IGF-1 signaling; no clinical data |
| GI Motility (ipamorelin) | Moderate | Phase 2 (Greenwood 2012) | Separate mechanism from GH; postoperative ileus indication |
No dedicated combination RCT: The Teichman 2006 study evaluated CJC-1295 alone. No published Phase 2 or Phase 3 RCT has specifically evaluated the CJC-1295 + ipamorelin combination. The synergy evidence comes from GHRH + GHRP combination studies using different compounds.
Body composition data is indirect: The GH and IGF-1 increases are well-documented, but the downstream effects on lean mass and fat loss in healthy adults have not been studied in dedicated RCTs. The body composition claims rest on the established anabolic effects of GH/IGF-1 signaling rather than direct trial evidence.
Long-term data is limited: The Teichman study extended to 28 days. No long-term (12+ month) human safety data exists for CJC-1295. The Sigalos 2018 review found no evidence of pituitary desensitization, but this is based on aggregate clinical experience rather than controlled long-term trials.
What is well-established: The pharmacokinetics of both compounds, the GH/IGF-1 response to CJC-1295, ipamorelin's selectivity for GH over cortisol/prolactin, and the GHRH+GHRP synergy mechanism are all supported by peer-reviewed data. The safety profile compares favorably to exogenous HGH.
Purgo Labs offers third-party tested CJC-1295 (with and without DAC) and ipamorelin with full Certificates of Analysis. Independent purity verification on every batch.
Shop CJC-1295 + Ipamorelin at Purgo LabsCJC-1295 with DAC (Drug Affinity Complex) has a half-life of 6–8 days due to albumin binding, producing a sustained elevation of GH. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of 30 minutes and produces a pulsatile GH release that more closely mimics natural physiology. Most researchers prefer the without-DAC version when stacking with ipamorelin to preserve natural GH pulsatility.
The combination is popular because CJC-1295 (a GHRH analog) and ipamorelin (a GHRP/ghrelin mimetic) work through complementary mechanisms that amplify each other's GH-releasing effects. CJC-1295 increases the amplitude of GH pulses; ipamorelin increases the frequency. Together they produce GH release 2–10x greater than either alone, while ipamorelin's selectivity minimizes cortisol and prolactin side effects common with older GHRPs.
The Teichman et al. 2006 study (Journal of Clinical Endocrinology & Metabolism) was the key Phase 2 clinical trial for CJC-1295 with DAC. It enrolled 65 healthy adults and showed dose-dependent increases in mean GH concentrations (2–10 fold) and IGF-1 levels (1.5–3 fold) that were sustained for 6 days after a single injection. This pharmacokinetic profile established CJC-1295 DAC as a long-acting GHRH analog.
Yes — ipamorelin is the most GH-selective GHRP studied to date. Unlike GHRP-2 and GHRP-6, ipamorelin does not significantly stimulate cortisol, prolactin, or ACTH at standard doses. The Raun et al. 1998 study (European Journal of Endocrinology) established this selectivity profile, which is why ipamorelin replaced older GHRPs in most research protocols.
Clinical data for CJC-1295 alone showed IGF-1 increases of 1.5–3 fold sustained for up to 28 days with repeated dosing (Teichman 2006). Ipamorelin alone produces acute GH spikes without sustained IGF-1 elevation. The combination produces sustained IGF-1 elevation comparable to CJC-1295 alone, with the added benefit of more physiological pulsatile GH release from the ipamorelin component.
CJC-1295 side effects in clinical trials included transient flushing, injection site reactions, and headache (most common at higher doses). Ipamorelin's side effect profile is notably mild — the Raun 1998 study showed no significant cortisol, prolactin, or ACTH elevation. Water retention and mild joint discomfort are reported with prolonged use at high doses, consistent with GH-related effects.
Sermorelin is the original GHRH analog (full 44-amino-acid sequence) while CJC-1295 is a modified 29-amino-acid fragment with enhanced stability. CJC-1295 without DAC has a similar half-life to sermorelin (~30 minutes) but greater potency per microgram. CJC-1295 with DAC has a dramatically longer half-life (6–8 days) vs sermorelin's ~10 minutes. The ipamorelin component adds a synergistic GHRP effect that sermorelin alone cannot provide.
GHRH analogs (CJC-1295, sermorelin) act on the GHRH receptor to increase cAMP and stimulate GH synthesis and release. GHRPs (ipamorelin, GHRP-6) act on the ghrelin receptor (GHS-R1a) through a separate intracellular pathway involving protein kinase C. When both pathways are activated simultaneously, the GH release is multiplicative rather than additive — studies show 2–10x greater GH output vs either compound alone.
Medical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.